Reaction

Pancreatic Carcinoma Recurrent reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 234 reports · 5 co-occurring drugs

As of the last recalculation, Pancreatic Carcinoma Recurrent appears in 234 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 202.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Pancrelipase64202.6203.0
Gemcitabine2460.360.3
Gemcitabine Hydrochloride2751.051.1
Irinotecan Hydrochloride642.642.6
Olaparib835.235.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.